This publication explores how partnerships between pharmaceutical companies and global health actors can be more strategic, equitable, and impact-driven.
Drawing on lessons from existing collaborations, the paper examines what works, where partnerships fall short, and how power dynamics, governance structures, and expectations shape outcomes. It offers practical insights for funders, implementers, and industry partners seeking to strengthen collaboration, align incentives, and design partnerships that deliver sustainable health impact while responding to evolving global health priorities.
